Antitope Limited, UK. Announces EpiScreen™ Collaboration with UCB Celltech
12th December 2007 -Antitope Ltd. today announced a research collaboration with UCB Celltech ("UCB") where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic monoclonal antibodies.
"We are very pleased to be working with UCB whom we recognize as a world-class company in the development and commercialization of therapeutic antibodies" said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "We look forward to assisting UCB in selecting therapeutic antibodies with a low potential for immunogenicity"
About Antitope
Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope's Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope is a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/.
About UCB Celltech
UCB Celltech is the UK branch of UCB, Brussels, Belgium (http://www.ucb-group.com), a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.
For further information contact:
Dr Neil Butt
Business Development Director
Antitope
Tel: +44 (0)1223 496190
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Dr. Ian Weatherhead
Global R&D Communications
UCB
Tel: 0044 (0)1753 447500
Email: r& This e-mail address is being protected from spambots. You need JavaScript enabled to view it